Jose G. Trevino

Virginia Commonwealth University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (8)

Directed acyclic graph for Cox proportional hazards regression. Directed acyclic graph representing all variables considered in building multivariable models for the Cox proportional hazards regression representing the associations of muscle changes with PDAC outcomes.

Year:

2025

Directed acyclic graph for generalized linear model. Directed acyclic graph representing all variables considered in building multivariable models for the generalized linear models representing the associations of PDAC diagnosis with post-diagnosis muscle changes.

Year:

2025

Background: Muscle loss influences pancreatic ductal adenocarcinoma (PDAC) outcomes, but treatment-related edema may cause overestimation of total skeletal muscle area (tSMA), confounding our understanding of muscle changes. However, no studies have quantified the impact of edema on tSMA and psoas skeletal muscle area (pSMA) changes. Thus, we sought to (i) assess the impact of edema on tSMA and pSMA changes between diagnosis and follow-up and (ii) explore the utility of pSMA as a clinically relevant measure of muscle and muscle loss among patients with PDAC. Methods: Body composition was measured using CT scans at diagnosis and follow-up from 95 patients enrolled in the Florida Pancreas Collaborative cohort study. Edema was assessed by opacifications in subcutaneous fat, and tSMA and pSMA changes were expressed as percent change between diagnosis and follow-up. We used multivariable generalized linear models to estimate mean tSMA and pSMA changes overall and by edema status. Spearman correlation was used to measure interrelationships of tSMA and pSMA. Results: tSMA increased between diagnosis and follow-up (Δ = 0.66) but only in patients with edema (Δ = 3.35) whereas non-edematous patients lost tSMA (Δ = −2.03). Conversely, pSMA decreased regardless of edema status. Furthermore, tSMA and pSMA were strongly correlated overall ( r = 0.75) and in non-edematous patients ( r = 0.83). Conclusions: Edema inflated estimates of tSMA at follow-up in patients with PDAC, but pSMA was impervious to edema and may represent a suitable proxy for tSMA. Impact: pSMA is a reliable measure of muscle and muscle loss and should be considered in future studies assessing muscle loss in patients with PDAC.

Year:

2025

Supplementary Figure 1 shows (A) spider plots of Log 2 of individual tumor volumes, (B) growth curves representing average Log 2 tumor volumes, (C) spider plots of Log 2 of proportional changes in tumor volume, and (D) growth curves showing Log2 proportional changes in tumor volume of the data shown in Figures 1 and 2.

Year:

2024

Although patient-derived xenografts (PDX) are commonly used for preclinical modeling in cancer research, a standard approach to in vivo tumor growth analysis and assessment of antitumor activity is lacking, complicating the comparison of different studies and determination of whether a PDX experiment has produced evidence needed to consider a new therapy promising. We present consensus recommendations for assessment of PDX growth and antitumor activity, providing public access to a suite of tools for in vivo growth analyses. We expect that harmonizing PDX study design and analysis and assessing a suite of analytical tools will enhance information exchange and facilitate identification of promising novel therapies and biomarkers for guiding cancer therapy.

Year:

2024

Although patient-derived xenografts (PDX) are commonly used for preclinical modeling in cancer research, a standard approach to in vivo tumor growth analysis and assessment of antitumor activity is lacking, complicating the comparison of different studies and determination of whether a PDX experiment has produced evidence needed to consider a new therapy promising. We present consensus recommendations for assessment of PDX growth and antitumor activity, providing public access to a suite of tools for in vivo growth analyses. We expect that harmonizing PDX study design and analysis and assessing a suite of analytical tools will enhance information exchange and facilitate identification of promising novel therapies and biomarkers for guiding cancer therapy.

Year:

2024

Supplementary Figure 1 shows (A) spider plots of Log 2 of individual tumor volumes, (B) growth curves representing average Log 2 tumor volumes, (C) spider plots of Log 2 of proportional changes in tumor volume, and (D) growth curves showing Log2 proportional changes in tumor volume of the data shown in Figures 1 and 2.

Year:

2024

PURPOSE Clinical trials determine safety and efficacy of cancer therapeutics and establish standards of care. Minority patient participation in cancer clinical trials is dismal. We aimed to determine the impact of eligibility criteria on disparities in pancreatic ductal adenocarcinoma (PDAC) clinical trial candidacy. METHODS Traditional PDAC trial eligibility criteria were obtained from ClinicalTrials.gov. Patients with PDAC who sought care at Virginia Commonwealth University Health from 2010 to 2019 were included. Clinical data were obtained from billing codes and discrete values in the electronic medical record. Eligibility criteria differences between racial groups were determined using chi-squared tests and unconditional maximum likelihood-based odds ratios. RESULTS Among 676 patients, most identified as Black or White race (42.5% and 51.6%, respectively). Using traditional criteria, Black patients were more likely to be ineligible for participation compared with White patients (42.4% v 33.2%, P = .023) secondary to hypoalbuminemia (14.1% v 7.9%, P = .023), HIV (3.1% v 0.3%, P = .010), hepatitis B (1.7% v 0%, P = .043), and hepatitis C (9.1% v 3.4%, P = .005). Black patients were also numerically more likely to be ineligible because of renal dysfunction, recent coronary stenting, and uncontrolled diabetes mellitus. Prior cancer treatment excluded fewer Black than White patients (9.1% v 14.0%, P = .072), most attributable to lower rates of neoadjuvant chemotherapy received. Strategic eligibility criteria revisions could equalize ineligibility rates between Black and White patients (26.8% v 24.8%, P = .581). CONCLUSION Traditional eligibility criteria differentially exclude Black patients from participating in PDAC clinical trials. These criteria perpetuate disparities, limit generalizability, and are often not medically justifiable. Revised criteria may improve participant diversity, without compromising safety or study results.

Year:

2022

Collaborators (33)

Lawrence Rubinstein

Statistician

National Cancer Institute

UNITED STATES
View details

Sylvia Crowder

Assistant Member

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Tiago Biachi de Castria

Associate Professor

University of South Florida

UNITED STATES
View details

Xuefeng Wang

Associate Member/Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Michael A. Davies

-

UNITED STATES
View details

Ghulam Rasool

Assistant Member

Moffitt Cancer Center

UNITED STATES
View details

Min Jin Ha

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Lisa McShane

Associate Director, Division of Cancer Treatment & Diagnosis

National Cancer Institute

UNITED STATES
View details

Vic VELANOVICH

University of South Florida

UNITED STATES
View details

Sarah Judge

Research Assistant Professor

University of Florida

UNITED STATES
View details

Jeffrey Chuang

Jackson Laboratory

UNITED STATES
View details

Qianxing Mo

Senior Member

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Alana Welm

Chair

Huntsman Cancer Institute

UNITED STATES
View details

Nicholas Mitsiades

Professor

University of California, Davis

UNITED STATES
View details

Bryan Welm

Associate Professor

Huntsman Cancer Institute

UNITED STATES
View details

Meenhard Herlyn

Professor, Director

The Wistar Institute

UNITED STATES
View details

Xuelin Huang

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jing Wang

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Ryan C. Fields

University of Rochester

UNITED STATES
View details

Luis G Carvajal‐Carmona

Professor

University of California, Davis

UNITED STATES
View details

Funda Meric-Bernstam

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Kun Jiang

-

UNITED STATES
View details

Salma Kaochar

Assistant Professor

Baylor College of Medicine

UNITED STATES
View details

Li Ding

Associate Professor

Washington University in Saint Louis School of Medicine

UNITED STATES
View details

Andrew Judge

Professor

University of Florida

UNITED STATES
View details

J. Chuck Harrell

Virginia Commonwealth University

UNITED STATES
View details

Jose Pimiento

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Dung-Tsa Chen

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Michael Lewis

Baylor College of Medicine

UNITED STATES
View details

Paul Stewart

Research Associate Professor

University of Utah

UNITED STATES
View details

Christopher J. Whelan

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Soner Koc

GlaxoSmithKline Research and Development

UNITED STATES
View details

Aleksandra Karolak

Assistant Professor - Secondary Appointment

Moffitt Cancer Center

UNITED STATES
View details